Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.
Isabelle MonnetAlain VergnenègreGilles RobinetHenri BerardRegine LamyLionel FalcheroSabine VieillotRoland SchottCharles RicordelStephane ChouabePascal ThomasRadj GervaisAnne MadroszykSamir AbdicheAnne Marie ChiappaLaurent GreillierChantal DecroisetteJean-Bernard AuliacChristos Chouaidnull nullPublished in: Therapeutic advances in medical oncology (2021)
The significant BR rate difference between the two arms suggests that upfront BR is not mandatory in aNSCLC with aBM but this trial failed to show that deferring BR for aBM is superior in terms of PFS from upfront BR.
Keyphrases
- phase iii
- open label
- clinical trial
- phase ii
- double blind
- small cell lung cancer
- placebo controlled
- early stage
- radiation therapy
- high grade
- phase ii study
- randomized controlled trial
- study protocol
- advanced non small cell lung cancer
- radiation induced
- white matter
- resting state
- multiple sclerosis
- epidermal growth factor receptor
- metastatic colorectal cancer
- rectal cancer